[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350350-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350350-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ferroptosis-as-a-novel-targeted-therapy-in-gynecological-malignant-tumors","Ferroptosis as a novel targeted therapy in gynecological malignant tumors","","Ferroptosis is an emerging form of regulated cell death driven by iron-dependent lipid peroxidation and offers a promising therapeutic target in oncology. Gynecological malignancies, including cervical, endometrial, and ovarian cancers, frequently develop therapeutic resistance through disrupted cell-death regulation. This review summarizes cancer-specific ferroptosis regulatory networks and links them to mechanisms of vulnerability, including HPV-driven oxidative stress in cervical cancer, ELK1-mediated GPX4 upregulation in endometrial cancer, and iron overload with p53- and microenvironment-mediated modulation in ovarian cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ferroptosis-as-a-novel-targeted-therapy-in-gynecological-malignant-tumors/350350/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ferroptosis-as-a-novel-targeted-therapy-in-gynecological-malignant-tumors/350350.png","ImageObject",300,407,{"name":42,"@type":43},"Adam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is ferroptosis and why is it considered a therapeutic target?","Question",{"text":63,"@type":64},"Ferroptosis is regulated cell death driven by iron-dependent lipid peroxidation. Its control is tightly connected to cancer survival and therapy resistance, making it a potential targeted therapy strategy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does ferroptosis relate to cervical cancer mechanisms?",{"text":68,"@type":64},"The review highlights that high-risk HPV oncoproteins (E6/E7) rewire oxidative stress and lipid metabolism, creating stage-dependent ferroptosis vulnerability and supporting combination approaches with immunotherapy.",{"name":70,"@type":61,"acceptedAnswer":71},"Which mechanisms are emphasized for endometrial and ovarian cancers?",{"text":72,"@type":64},"For endometrial cancer, ELK1-mediated GPX4 upregulation contributes to chemoresistance and suggests ferroptosis induction to overcome treatment failure. For ovarian cancer, iron overload promotes metastasis, while p53, lipid-modifying enzymes, and tumor microenvironment signals modulate ferroptosis sensitivity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350350,1790242399,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Yu etal. Discover Oncology (2026) 17:827 [https://doi.org/10.1007/s12672-026-04686-x](https://doi.org/10.1007/s12672-026-04686-x)  \nDiscover Oncology  \nREVIEW Open Access  \nFerroptosis as a novel targeted therapy in gynecological malignant tumors  \nCongxiang Yu1,2, Yuefei Li3, Yangxin Fu4, Ruizhe Yang4, Zorica Nakevska4, Pooja Praveen Kumar4, An Nhien Tong5, NanYang2, Dan Liu6, Chao Chen7, Ling Ouyang2 and Zhijun Xia8*  \n*Correspondence: Zhijun Xia [xiazhijun_2024@qq.com](xiazhijun_2024@qq.com)  \nFull list of author information is available at the end of the article  \nAbstract  \nFerroptosis, an emerging form of regulated cell death driven by iron-dependent lipid peroxidation, represents a promising therapeutic target in oncology. Gynecological malignancies—cervical, endometrial, and ovarian cancers—are frequently associated with therapeutic resistance due to defective cell death regulation. This review delineates cancer-specific ferroptosis regulatory networks across these malignancies. In cervical cancer, high-risk HPV oncoproteins (E6/E7) rewire oxidative stress and lipid metabolism, leading to stage-dependent ferroptosis vulnerability and supporting combination approaches with immunotherapy. In endometrial cancer, ELK1-mediated GPX4 upregulation drives chemoresistance, highlighting ferroptosis induction as a strategy to overcome treatment failure. In ovarian cancer, iron overload promotes metastasis, while p53, lipid-modifying enzymes (SCD1/FADS2), and the tumor microenvironment (e. g., CXCL8/CXCR2 axis) modulate ferroptosis sensitivity, providing avenues to target aggressive subtypes such as clear cell carcinoma. We conclude that targeting ferroptosis offers a transformative strategy for gynecological cancers. Keywords Gynecological, Malignant tumors, Ferroptosis, Cervical carcinoma, Endometrial carcinoma, Ovarian carcinoma, Glutathione peroxidase 4  \nGynecological malignancies, including cervical, endometrial, and ovarian carcinomas, represent a major global health burden due to their high prevalence and mortality [1]. Like many cancers, their progression and resistance to therapy are frequently linked todysregulated cell death pathways. Cell death plays a vital role in normal development, homeostasis, and the prevention of hyperproliferative diseases, including cancer [2].  \nFerroptosis, a distinct type of cell death characterized by iron-dependent lipid peroxidation, was first identified by Dixon in 2012. This form of cell death is unique from apoptosis, necrosis, and autophagy, differing in its morphological, biochemical, and genetic characteristics. Dixon’s research revealed that the cell death pathway activated by the oncogenic RAS-selective small molecule erastin differs from thepathways commonly involved in programmed cell death. Erastin induces ferroptosis in cancer cells through the accumulation of deferoxamine (DFO)-sensitive reactive oxygen species (ROS), even in cells lacking a functional mitochondrial electron transport chain (ETC). This process  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nYu et al.","cbCaito4kMZl6Flj","https://ap.wps.com/l/cbCaito4kMZl6Flj","pdf",1308271,11,"English","# Abstract\n## Background and significance\n## Ferroptosis mechanism and regulation\n## Links to therapy resistance\n## Cancer-specific regulatory networks","[{\"question\":\"What is ferroptosis and why is it considered a therapeutic target?\",\"answer\":\"Ferroptosis is regulated cell death driven by iron-dependent lipid peroxidation. Its control is tightly connected to cancer survival and therapy resistance, making it a potential targeted therapy strategy.\"},{\"question\":\"How does ferroptosis relate to cervical cancer mechanisms?\",\"answer\":\"The review highlights that high-risk HPV oncoproteins (E6/E7) rewire oxidative stress and lipid metabolism, creating stage-dependent ferroptosis vulnerability and supporting combination approaches with immunotherapy.\"},{\"question\":\"Which mechanisms are emphasized for endometrial and ovarian cancers?\",\"answer\":\"For endometrial cancer, ELK1-mediated GPX4 upregulation contributes to chemoresistance and suggests ferroptosis induction to overcome treatment failure. For ovarian cancer, iron overload promotes metastasis, while p53, lipid-modifying enzymes, and tumor microenvironment signals modulate ferroptosis sensitivity.\"}]","Ferroptosis as a novel targeted therapy in gynecological malignant tumors | PDF",1790088584,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8062abba79d56b16fcd6a97397c3761f.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42c19132cd54f67e8fd4bf7d7ef21850.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc71ecea57eb3fabc58a10586ce9c012.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f0702ca013f428cd465f30ac5c375e3.webp",980,1306]